[Prognosis of pancreatic adenocarcinoma].
Escourrou
J
J
Service de Gastroentérologie, Hôpital de Rangueil, 1 Avenue Jean Poulhes, 31403 Toulouse. escourrou.j@chu-toulouse.fr
Buscail
L
L
Pages
P
P
Moreau
J
J
Faure
P
P
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000401:mortality* / Q000601:surgery; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000401:mortality* / Q000601:surgery; D016577:Pancreaticoduodenectomy; D018579:Patient Selection; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012737:Sex Factors; D013997:Time Factors; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine
Pronostic de l'adénocarcinome pancréatique.